KRAS and metastatic colorectal cancer: These results are in line with those of a recent meta-analysis of 12 randomized trials, which found that in medically treated patients with unresectable metastatic colorectal cancer, the prognostic value of PTL was restricted to the KRAS wild-type population [27].